This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through March 4, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Beyond Air (XAIR) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Beyond Air (XAIR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Beyond Air, Inc. (XAIR) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Beyond Air, Inc. (XAIR) delivered earnings and revenue surprises of 18.03% and 20.20%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Beyond Air, Inc. (XAIR) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Beyond Air, Inc. (XAIR) delivered earnings and revenue surprises of 2.17% and 70.65%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Beyond Air, Inc. (XAIR) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Beyond Air, Inc. (XAIR) delivered earnings and revenue surprises of -52.27% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Beyond Air, Inc. (XAIR) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Beyond Air, Inc. (XAIR) delivered earnings and revenue surprises of -2.38% and 100%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for January 27th
by Zacks Equity Research
ARAY, XAIR, and EMKR have been added to the Zacks Rank #5 (Strong Sell) List on January 27, 2022
Implied Volatility Surging for Beyond Air (XAIR) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Beyond Air (XAIR) stock based on the movements in the options market lately.
Beyond Air, Inc. (XAIR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Beyond Air, Inc. (XAIR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Beyond Air, Inc. (XAIR) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Beyond Air, Inc. (XAIR) delivered earnings and revenue surprises of -63.16% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Beyond Air, Inc. (XAIR) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Beyond Air, Inc. (XAIR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Beyond Air (XAIR) is in Overbought Territory: What's Next?
by Zacks Equity Research
Beyond Air (XAIR) has moved higher as of late, but there could definitely be trouble on the horizon for this company
Will Beyond Air, Inc. (XAIR) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Beyond Air, Inc. (XAIR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Share Gain in Core Markets to Aid Medtronic (MDT) Q4 Earnings
by Zacks Equity Research
Growing momentum in capital equipment purchases might have aided Medtronic (MDT) Q4 earnings.
4 Biotech Stocks Set to Outpace Q1 Earnings Estimates
by Zacks Equity Research
Let us take a look at some drug/biotech stocks that are poised to beat on first-quarter earnings.
Beyond Air, Inc. (XAIR) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Beyond Air, Inc. (XAIR) delivered earnings and revenue surprises of -6.45% and -25.50%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Beyond Air, Inc. (XAIR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Beyond Air, Inc. (XAIR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will AIT Therapeutics, Inc. (XAIR) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
AIT Therapeutics, Inc. (XAIR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate AIT Therapeutics, Inc. (XAIR) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
AIT Therapeutics, Inc. (XAIR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AIT Therapeutics, Inc. (XAIR) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
AIT Therapeutics, Inc. (XAIR) delivered earnings and revenue surprises of -30.30% and -45.39%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
AIT Therapeutics, Inc. (XAIR) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
AIT Therapeutics, Inc. (XAIR) delivered earnings and revenue surprises of -15.15% and 3.36%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
AIT Therapeutics, Inc. (XAIR) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
AIT Therapeutics, Inc. (XAIR) delivered earnings and revenue surprises of -90.91% and -49.84%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?